These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27789138)

  • 1. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
    Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
    Zhang Z; Cao C; Sun S; Xu Q
    Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
    Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
    Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
    Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
    Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
    J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new Syk inhibitors through structure-based virtual screening.
    Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.
    Matsumaru T; Inai M; Ishigami K; Iwamatsu T; Maita H; Otsuguro S; Nomura T; Matsuda A; Ichikawa S; Sakaitani M; Shuto S; Maenaka K; Kan T
    Bioorg Med Chem Lett; 2017 May; 27(10):2144-2147. PubMed ID: 28385506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.
    Patel L; Chandrasekhar J; Evarts J; Haran AC; Ip C; Kaplan JA; Kim M; Koditek D; Lad L; Lepist EI; McGrath ME; Novikov N; Perreault S; Puri KD; Somoza JR; Steiner BH; Stevens KL; Therrien J; Treiberg J; Villaseñor AG; Yeung A; Phillips G
    J Med Chem; 2016 Apr; 59(7):3532-48. PubMed ID: 26980109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
    Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
    J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
    Coffey G; Rani A; Betz A; Pak Y; Haberstock-Debic H; Pandey A; Hollenbach S; Gretler DD; Mant T; Jurcevic S; Sinha U
    J Clin Pharmacol; 2017 Feb; 57(2):194-210. PubMed ID: 27406873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and profiling of a selective and efficacious Syk inhibitor.
    Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
    J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
    Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
    Life Sci; 2017 Dec; 191():166-174. PubMed ID: 29056373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.
    Kaur M; Singh M; Silakari O
    Future Med Chem; 2017 Jul; 9(11):1193-1211. PubMed ID: 28722479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.